Details

Project TitleSelective Human Sirtuin-2 Inhibitors, the Therapeutic Candidate for Huntington's Disease
Track Code2012-145
Short Description

Selective human sirtuin-2 inhibitors for use in treating Huntington's disease. 
#therapeutics #cns #huntingtonsdisease 

Abstract

Northwestern researchers have discovered a new series of selective human sirtuin-2 inhibitors which show excellent neuronal protection in the Huntington's disease model. Human sirtuin-2 is a therapeutic target of numerous age-related neuronal degenerative diseases, including Huntington's disease, Parkinson's disease, and Alzheimer's disease. These new compounds were developed using pharmacophere exploration and SAR analysis of a lead compound. This group exhibits improved potency, selectivity and bioavailability and thus are expected to exhibit a promising pharmacological profile. 

 
TagsCNS: Huntington's Disease, THERAPEUTICS: CNS
 
Posted DateMay 29, 2014 2:35 PM

Inventor(s)

Richard B. Silverman* 
Hua Wang 
Mohammad Khanfar

Applications

Treatment of neurodegenerative diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease 

Advantages

  • More potent and selective than previous human sirtuin-2 inhibitors 
  • Improved pharmaceutical properties and promising drug candidate

Publications

IP Status

A patent application has been filed. 

Contact Information

Vara Josyula, PhD
Invention Manager 
(p) 847.491.4456

(e) vara.josyula@northwestern.edu